Apimeds appoints Dr. Christopher Kim as Chief Scientific Officer

Apimeds Pharmaceuticals US, Inc.

Dr. Christopher Kim appointed Chief Scientific Officer effective August 5, 2026.
He will lead scientific, clinical, and regulatory development of the APITOX program.
Dr. Kim has extensive expertise in APITOX research, development, and clinical advancement.
Appointment provides continuity and strengthens long-term development strategy toward commercialization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.